AR061024A1 - Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona. - Google Patents

Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona.

Info

Publication number
AR061024A1
AR061024A1 ARP070102159A ARP070102159A AR061024A1 AR 061024 A1 AR061024 A1 AR 061024A1 AR P070102159 A ARP070102159 A AR P070102159A AR P070102159 A ARP070102159 A AR P070102159A AR 061024 A1 AR061024 A1 AR 061024A1
Authority
AR
Argentina
Prior art keywords
pyrimidin
acetyl
beta
amino
maleate
Prior art date
Application number
ARP070102159A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38287962&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR061024(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR061024A1 publication Critical patent/AR061024A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente se refiere a sales de 5-amino-3-(2',3'-di-O-acetil-beta-D-ribofuranosil)-3H-tiazolo[4,5-d]pirimidin-2-ona y formas cristalinas de la misma, su produccion y uso, y preparaciones farmacéuticas que contienen dichas sales y formas cristalinas. Reivindicacion 1: Una sal de maleato de 5-amino-3-(2',3'-di-O-acetil-beta-D-ribofuranosil)-3H-tiazolo[4,5-d]pirimidin-2-ona.
ARP070102159A 2006-05-22 2007-05-18 Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona. AR061024A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80242506P 2006-05-22 2006-05-22

Publications (1)

Publication Number Publication Date
AR061024A1 true AR061024A1 (es) 2008-07-30

Family

ID=38287962

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102159A AR061024A1 (es) 2006-05-22 2007-05-18 Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona.

Country Status (15)

Country Link
US (1) US20100286081A1 (es)
EP (1) EP2027139A1 (es)
JP (1) JP2009537603A (es)
KR (1) KR20090029730A (es)
CN (1) CN101528762A (es)
AR (1) AR061024A1 (es)
AU (1) AU2007253302A1 (es)
CA (1) CA2652857A1 (es)
CL (1) CL2007001427A1 (es)
IL (1) IL195408A0 (es)
MX (1) MX2008014891A (es)
NO (1) NO20084882L (es)
PE (1) PE20080179A1 (es)
TW (1) TW200813081A (es)
WO (1) WO2007135134A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2019113A1 (en) * 2007-07-26 2009-01-28 Anadys Pharmaceuticals, Inc. New Crystalline Salts of 5-Amino-3-(2',3'-di-O-acetyl-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one
SI2937350T1 (en) 2008-04-23 2018-05-31 Gilead Sciences, Inc. 1'-SUBSTITUTED CARBON-NUCLEOUS ANALOGS FOR ANTIVIRUSAL TREATMENT
DK2480559T3 (da) 2009-09-21 2013-08-05 Gilead Sciences Inc Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger
EA025311B1 (ru) 2010-07-19 2016-12-30 Гайлид Сайэнсиз, Инк. Способы получения диастереомерно чистых фосфорамидатных пролекарств
UA111163C2 (uk) 2010-07-22 2016-04-11 Гайлід Сайєнсіз, Інк. Способи й сполуки для лікування вірусних інфекцій paramyxoviridae
TWI767201B (zh) 2014-10-29 2022-06-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
CR20170237A (es) 2014-12-08 2017-08-10 Hoffmann La Roche Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CN107427514B (zh) 2015-03-16 2021-07-13 豪夫迈·罗氏有限公司 使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗
WO2016180691A1 (en) 2015-05-08 2016-11-17 F. Hoffmann-La Roche Ag Novel oxathiolane carboxylic acids and derivatives for the treatment and prophylaxis of virus infection
EP4001283A1 (en) 2015-05-12 2022-05-25 F. Hoffmann-La Roche AG Substituted aminothiazolopyrimidinedione derivatives for the treatment and prophylaxis of virus infection
CN107820498B (zh) 2015-06-30 2020-06-19 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的取代的氨基噻唑并嘧啶二酮
LT3349758T (lt) 2015-09-16 2022-07-11 Gilead Sciences, Inc. Arenavirusų šeimos virusinių infekcijų gydymo būdai
CA3048768A1 (en) 2017-01-06 2018-07-12 F. Hoffmann-La Roche Ag Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds
EP3595672B1 (en) 2017-03-14 2023-09-06 Gilead Sciences, Inc. Compounds for use in methods of treating feline coronavirus infections
WO2018204198A1 (en) 2017-05-01 2018-11-08 Gilead Sciences, Inc. Crystalline forms of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
EP3651734A1 (en) 2017-07-11 2020-05-20 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
CN118662520A (zh) 2020-01-27 2024-09-20 吉利德科学公司 用于治疗SARS CoV-2感染的方法
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
EP4132651A1 (en) 2020-04-06 2023-02-15 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CN115666570A (zh) 2020-05-29 2023-01-31 吉利德科学公司 瑞德西韦治疗方法
AU2021296841A1 (en) 2020-06-24 2023-02-16 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
EP4424372A2 (en) 2020-08-27 2024-09-04 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
IL315102A (en) 2022-03-02 2024-10-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1269766B1 (de) * 2000-04-06 2005-08-10 Siemens Aktiengesellschaft Bereitstellen von ergänzenden diensten in einem paketvermittelnden kommunikationsnetz
US7321033B2 (en) * 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
EP1451203B1 (en) * 2001-11-27 2009-11-11 Anadys Pharmaceuticals, Inc. 3-beta-d-ribofuranosylthiazolo(4,5-delta)pyridimine nucleosides and uses thereof
BRPI0414045A (pt) * 2003-09-05 2006-10-24 Anadys Pharmaceuticals Inc administração de ligantes de tlr7 e pró-medicamentos dos mesmos para tratamento de infecção por vìrus de hepatite c
CN1964985A (zh) * 2004-06-07 2007-05-16 阿纳迪斯药物公司 3－β－D－呋喃核糖基噻唑并[4,5－d]嘧啶核苷类及其应用

Also Published As

Publication number Publication date
WO2007135134A1 (en) 2007-11-29
PE20080179A1 (es) 2008-04-22
US20100286081A1 (en) 2010-11-11
CL2007001427A1 (es) 2008-05-16
MX2008014891A (es) 2009-01-29
CA2652857A1 (en) 2007-11-29
NO20084882L (no) 2008-12-17
IL195408A0 (en) 2011-08-01
CN101528762A (zh) 2009-09-09
AU2007253302A1 (en) 2007-11-29
KR20090029730A (ko) 2009-03-23
EP2027139A1 (en) 2009-02-25
TW200813081A (en) 2008-03-16
JP2009537603A (ja) 2009-10-29

Similar Documents

Publication Publication Date Title
AR061024A1 (es) Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona.
BRPI0924183B8 (pt) inibidores de cdk4/6 quinase, seus usos e sua forma cristalina iii, e formulação farmacêutica
AR106702A2 (es) Uso de un anticuerpo antagonista anti-ngf para la preparación de un medicamento
UY30136A1 (es) Sal especifica, forma anhidra y cristalina de un derivado de dihidropteridiona
ECSP045221A (es) Sales de valsartan
BRPI0607545A2 (pt) composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
CL2006001266A1 (es) Formas solidas cristalinas i, ii, iii, iv y v de tigeciclina; procedimiento de preparacion de las formas cristalinas ii, iv y v; composicion farmaceutica que comprende las formas cristalinas; y su uso para tratar infecciones bacterianas.
WO2007048064A3 (en) Amino-pyrimidines as casein kinase ii (ck2) modulators
BRPI0514372A (pt) inibidores de tiazol de frutose 1, 6-bisfosfatase
NO2014028I2 (no) Glukopyranosyl-substituerte benzenderivater, fremgangsmåte for fremstilling av disse, fysiologisk akseptable salter av slike forbindelser, medikamenter inneholdende slike forbindelser og kombinasjoner med andre aktive substanser samt deresanvendelse for fremstilling av medikamenter for behandling av sykdom
ECSP034436A (es) Sales de valsartan
BRPI0511933B8 (pt) derivados de quinazolinona, seu uso e seu processo de preparação, e composição farmacêutica
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
CL2012001966A1 (es) Formulación farmacéutica que comprende entre 100-150 mg/ml de un anticuerpo que se une específicamente al receptor a de il-17 humana, una solución acuosa de un buffer 5-30 mm de ácido glutámico ph 4,5-5,2, prolina 2-4% p/v y polisorbato-20 0,005-0,02% p/v; envase farmacéutico y kit que comprende dicha formulación; y su uso para tratar psoriasis.
AR063188A1 (es) Compuestos intermediarios para la preparacion de trans -5-cloro-2-netil-2,3,3a,12b- tetrahidro-1h-dibenz (2,3:6,7)- oxepina (4,5c) pirrol
EA200801663A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 1'-(1-МЕТИЛЭТИЛ)-4'-[(2-ФТОР-4-МЕТОКСИФЕНИЛ)МЕТИЛ]-5'-МЕТИЛ-1H-ПИРАЗОЛ-3'-O-β-D-ГЛЮКОПИРАНОЗИДА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
BRPI0517263A (pt) novos derivados de sulfonamida como moduladores do receptor de glicocorticóide para o tratamento de doenças inflamatórias
CU23932B1 (es) Sales farmacéuticamente aceptables de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo y sus usos en terapia
ECSP088209A (es) Nueva forma cristalina de un derivado de piridazino[4,5-b]indol
BRPI0822033A2 (pt) Composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal, e, kit
CL2007003472A1 (es) Sal fumarato de (alfa s,beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol; proceso de preparacion; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamie
BRPI0518993A2 (pt) composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto
BRPI0818690A2 (pt) Derivados de quinazolinediona, sua preparação e seus usos terapêuticos.
BRPI0620985B8 (pt) composição farmacêutica, e usos de derivados de triazina e sensibilizadores de insulina

Legal Events

Date Code Title Description
FB Suspension of granting procedure